Literature DB >> 23164597

Comparisons of detailed arterial healing response at seven months following implantation of an everolimus- or sirolimus-eluting stent in patients with ST-segment elevation myocardial infarction.

Takahiro Sawada1, Toshiro Shinke, Hiromasa Otake, Taiji Mizoguchi, Masamichi Iwasaki, Takuo Emoto, Daisuke Terashita, Takao Mizuguchi, Hiroshi Okamoto, Yosuke Matsuo, Sushi-ku Kim, Akira Takarada, Mitsuhiro Yokoyama.   

Abstract

BACKGROUND: The difference of arterial healing response following everolimus-eluting stent (EES) or sirolimus-eluting stent (SES) implantation in patients with ST-segment elevated myocardial infarction (STEMI) has not been compared in detail.
METHODS: Thirty-five patients with STEMI were randomly implanted with an EES or SES (23 EES, 12 SES). At seven months, neointimal thickness (NIT) and strut malapposition were evaluated by optical coherence tomography (OCT) and the grade and heterogeneity of neointimal coverage (NIC) and development of intra-stent thrombi were evaluated by angioscopy.
RESULTS: No significant differences were noted in clinical events experienced by the two groups, although one patient with an EES died following a papillary muscle rupture and one patient with a SES experienced sub-acute stent thrombosis. On OCT, although the EES implants showed a greater NIT than the SES implants (94.8 ± 88.8 μm vs 65.6 ± 63.3 μm, P<0.0001), both the EES and SES showed an excellent suppression of neointimal proliferation in the culprit lesion of STEMI. The frequency of uncovered and malapposed struts of EES was significantly lower than that of SES (2.7% vs. 15.7%, P<0.0001, 0.7% vs. 2.3%, P<0.0001, respectively). The ratio of stents fully covered with neointima of EES group was significantly higher than that of SES group (P=0.04). Angioscopic analysis also showed greater dominant NIC grade with homogenous NIC in EES than in SES (P=0.03, P=0.0002, respectively). The incidence of massive intra-stent thrombus of EES was lower than that of SES (P=0.05).
CONCLUSION: For patients with STEMI, EES may promote better arterial healing response than SES.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Angioscopy; Everolimus-eluting stent; OCT; STEMI

Mesh:

Substances:

Year:  2012        PMID: 23164597     DOI: 10.1016/j.ijcard.2012.10.043

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  10 in total

1.  A Randomized Comparison of the Healing Response Between the Firehawk Stent and the Xience Stent in Patients With ST-Segment Elevation Myocardial Infarction at 6 Months of Follow-Up (TARGET STEMI OCT China Trial): An Optical Coherence Tomography Study.

Authors:  Yuan He; Rutao Wang; Jianzheng Liu; Fei Li; Jiayi Li; Chengxiang Li; Jingyu Zhou; Zhijing Zhao; Wangwei Yang; Fangjun Mou; Jing Wang; Jing Kan; Xiaobo Li; Yan Li; Ming Zheng; Shaoliang Chen; Chao Gao; Ling Tao
Journal:  Front Cardiovasc Med       Date:  2022-06-01

Review 2.  Clinical outcomes of second- versus first-generation drug-eluting stents in patients with acute myocardial infarction: a meta-analysis of randomized controlled trials.

Authors:  Guodong Wu; Guoqiang Sun; Ruihong Zhao; Mingli Sun
Journal:  Arch Med Sci       Date:  2014-08-29       Impact factor: 3.318

3.  First-generation versus second-generation drug-eluting stents in current clinical practice: updated evidence from a comprehensive meta-analysis of randomised clinical trials comprising 31 379 patients.

Authors:  Eliano Pio Navarese; Mariusz Kowalewski; David Kandzari; Alexandra Lansky; Bartosz Górny; Lukasz Kołtowski; Ron Waksman; Sergio Berti; Giuseppe Musumeci; Ugo Limbruno; Rene J van der Schaaf; Malte Kelm; Jacek Kubica; Harry Suryapranata
Journal:  Open Heart       Date:  2014-08-21

4.  CVIT expert consensus document on primary percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI) in 2018.

Authors:  Yukio Ozaki; Yuki Katagiri; Yoshinobu Onuma; Tetsuya Amano; Takashi Muramatsu; Ken Kozuma; Satoru Otsuji; Takafumi Ueno; Nobuo Shiode; Kazuya Kawai; Nobuhiro Tanaka; Kinzo Ueda; Takashi Akasaka; Keiichi Igarashi Hanaoka; Shiro Uemura; Hirotaka Oda; Yoshiaki Katahira; Kazushige Kadota; Eisho Kyo; Katsuhiko Sato; Tadaya Sato; Junya Shite; Koichi Nakao; Masami Nishino; Yutaka Hikichi; Junko Honye; Tetsuo Matsubara; Sumio Mizuno; Toshiya Muramatsu; Taku Inohara; Shun Kohsaka; Ichiro Michishita; Hiroyoshi Yokoi; Patrick W Serruys; Yuji Ikari; Masato Nakamura
Journal:  Cardiovasc Interv Ther       Date:  2018-03-29

5.  Long-Term Efficacy and Safety of Everolimus-Eluting Stent Implantation in Japanese Patients with Acute Coronary Syndrome: Five-Year Real-World Data from the Tokyo-MD PCI Study.

Authors:  Shunji Yoshikawa; Takashi Ashikaga; Toru Miyazaki; Ken Kurihara; Kenzo Hirao
Journal:  J Interv Cardiol       Date:  2019-11-03       Impact factor: 2.279

6.  Comparison of First- and Second-Generation Drug-Eluting Stents in Patients with ST-Segment Elevation Myocardial Infarction Based on Pre-Percutaneous Coronary Intervention Thrombolysis in Myocardial Infarction Flow Grade.

Authors:  Yong Hoon Kim; Ae-Young Her; Myung Ho Jeong; Byeong-Keuk Kim; Sung-Jin Hong; Seunghwan Kim; Chul-Min Ahn; Jung-Sun Kim; Young-Guk Ko; Donghoon Choi; Myeong-Ki Hong; Yangsoo Jang
Journal:  J Clin Med       Date:  2021-01-19       Impact factor: 4.241

Review 7.  CVIT expert consensus document on primary percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI) update 2022.

Authors:  Yukio Ozaki; Hironori Hara; Yoshinobu Onuma; Yuki Katagiri; Tetsuya Amano; Yoshio Kobayashi; Takashi Muramatsu; Hideki Ishii; Ken Kozuma; Nobuhiro Tanaka; Hitoshi Matsuo; Shiro Uemura; Kazushige Kadota; Yutaka Hikichi; Kenichi Tsujita; Junya Ako; Yoshihisa Nakagawa; Yoshihiro Morino; Ichiro Hamanaka; Nobuo Shiode; Junya Shite; Junko Honye; Tetsuo Matsubara; Kazuya Kawai; Yasumi Igarashi; Atsunori Okamura; Takayuki Ogawa; Yoshisato Shibata; Takafumi Tsuji; Junji Yajima; Kaoru Iwabuchi; Nobuo Komatsu; Teruyasu Sugano; Masaru Yamaki; Shinichiro Yamada; Hiroaki Hirase; Yuusuke Miyashita; Fuminobu Yoshimachi; Masakazu Kobayashi; Jiro Aoki; Hirotaka Oda; Yoshiaki Katahira; Kinzo Ueda; Masami Nishino; Koichi Nakao; Ichiro Michishita; Takafumi Ueno; Taku Inohara; Shun Kohsaka; Tevfik F Ismail; Patrick W Serruys; Masato Nakamura; Hiroyoshi Yokoi; Yuji Ikari
Journal:  Cardiovasc Interv Ther       Date:  2022-01-12

8.  Drug-eluting stents for acute coronary syndrome: a meta-analysis of randomized controlled trials.

Authors:  Lishan Wang
Journal:  PLoS One       Date:  2013-09-05       Impact factor: 3.240

9.  CYP2C19 loss-of-function alleles are not associated with clinical outcome of clopidogrel therapy in patients treated with newer-generation drug-eluting stents.

Authors:  Ik Jun Choi; Yoon-Seok Koh; Mahn-Won Park; Sung Ho Her; Yun-Seok Choi; Chul-Soo Park; Hun-Jun Park; Pum-Joon Kim; Wook-Sung Chung; Ho-Sook Kim; Jae-Gook Shin; Ki-Bae Seung; Kiyuk Chang
Journal:  Medicine (Baltimore)       Date:  2016-06       Impact factor: 1.889

10.  Five-year major clinical outcomes between first-generation and second-generation drug-eluting stents in acute myocardial infarction patients underwent percutaneous coronary intervention.

Authors:  Yong Hoon Kim; Ae-Young Her; Seung-Woon Rha; Byoung Geol Choi; Se Yeon Choi; Jae Kyeong Byun; Ju Yeol Baek; Woong Gil Choi; Tae Soo Kang; Ji Hoon Ahn; Sang-Ho Park; Ahmed Mashaly; Jin Oh Na; Cheol Ung Choi; Hong Euy Lim; Eung Ju Kim; Chang Gyu Park; Hong Seog Seo; Dong Joo Oh
Journal:  J Geriatr Cardiol       Date:  2018-08       Impact factor: 3.327

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.